Aberrant Ca2+ handling in lysosomal storage disorders

Cell Calcium

Volumn 47, Issue 2, 2010, Pages 103-111

  Kiselyov, Kirill ^a   Yamaguchi, Soichiro ^b   Lyons, Christopher W ^a   Muallem, Shmuel ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Autophagy; Calcium; Cell death; Ion channels; Lysosomal storage diseases; Lysosomes; Mitochondria; Mucolipins; Signaling; TRPML1; TRPML3; Two pore channels

Indexed keywords

CALCIUM ION; CLUSTERIN; GLUCOSYLCERAMIDASE; RYANODINE RECEPTOR; SNARE PROTEIN; CARRIER PROTEIN;

CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL DEATH; ENDOCYTOSIS; GAUCHER DISEASE; HUMAN; LYSOSOME; LYSOSOME STORAGE DISEASE; MEMBRANE TRANSPORT; NIEMANN PICK DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ANIMAL; GENETICS; METABOLISM; MITOCHONDRION;

ANIMALS; CALCIUM SIGNALING; ENDOCYTOSIS; HUMANS; LYSOSOMAL STORAGE DISEASES; LYSOSOMES; MEMBRANE TRANSPORT PROTEINS; MITOCHONDRIA;

EID: 77549084219     PISSN: 01434160     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceca.2009.12.007     Document Type: Review

References (83)

1. Walkley S.U. Pathogenic cascades in lysosomal disease-Why so complex?. J. Inherit. Metab. Dis. 32 2 (2009) 181-189
2. Mach L. Biosynthesis of lysosomal proteinases in health and disease. Biol. Chem. 383 5 (2002) 751-756
3. Mullins C., and Bonifacino J.S. The molecular machinery for lysosome biogenesis. Bioessays 23 4 (2001) 333-343
4. Luzio J.P., et al. Membrane traffic to and from lysosomes. Biochem. Soc. Symp. 72 (2005) 77-86
5. Schilsky M.L., and Mistry P. Metabolic liver disease. Curr. Opin. Gastroenterol. 17 3 (2001) 221-231
6. Anderson N., and Borlak J. Drug-induced phospholipidosis. FEBS Lett. 580 23 (2006) 5533-5540
7. Schneider P., Korolenko T.A., and Busch U. A review of drug-induced lysosomal disorders of the liver in man and laboratory animals. Microsc. Res. Tech. 36 4 (1997) 253-275
8. Puertollano R., and Kiselyov K. TRPMLs: in sickness and in health. Am. J. Physiol. Renal. Physiol. 296 6 (2009) F1245-F1254
9. Kurz T., et al. Lysosomes in iron metabolism, ageing and apoptosis. Histochem. Cell Biol. 129 4 (2008) 389-406
10. Stroikin Y., et al. Testing the "garbage" accumulation theory of ageing: mitotic activity protects cells from death induced by inhibition of autophagy. Biogerontology 6 1 (2005) 39-47
11. Dong X.P., et al. The type IV mucolipidosis-associated protein TRPML1 is an endolysosomal iron release channel. Nature 455 7215 (2008) 992-996
12. Nixon R.A., Yang D.S., and Lee J.H. Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy 4 5 (2008) 590-599
13. Weimer J.M., et al. The neuronal ceroid lipofuscinoses: mutations in different proteins result in similar disease. Neuromol. Med. 1 2 (2002) 111-124
14. Venugopal B., et al. Chaperone-mediated autophagy is defective in mucolipidosis type IV. J. Cell Physiol. 219 2 (2009) 344-353
15. Todde V., Veenhuis M., and van der Klei I.J. Autophagy: principles and significance in health and disease. Biochim. Biophys. Acta 1792 1 (2009) 3-13
16. Ruivo R., et al. Molecular and cellular basis of lysosomal transmembrane protein dysfunction. Biochim. Biophys. Acta 1793 4 (2009) 636-649
17. Martina J.A., Lelouvier B., and Puertollano R. The calcium channel mucolipin-3 is a novel regulator of trafficking along the endosomal pathway. Traffic 10 8 (2009) 1143-1156
18. Kim H.J., et al. The Ca (2+) channel TRPML3 regulates membrane trafficking and autophagy. Traffic 10 8 (2009) 1157-1167
19. Ballabio A., and Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim. Biophys. Acta 1793 4 (2009) 684-696
20. Vergarajauregui S., et al. Autophagic dysfunction in mucolipidosis type IV patients. Hum. Mol. Genet. 17 17 (2008) 2723-2737
21. Eskelinen E.L., and Saftig P. Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim. Biophys. Acta 1793 4 (2009) 664-673
22. Terman A., et al. Lysosomal labilization. IUBMB Life 58 9 (2006) 531-539
23. Pryor P.R., et al. The role of intraorganellar Ca (2+) in late endosome-lysosome heterotypic fusion and in the reformation of lysosomes from hybrid organelles. J. Cell Biol. 149 5 (2000) 1053-1062
24. Luzio J.P., Bright N.A., and Pryor P.R. The role of calcium and other ions in sorting and delivery in the late endocytic pathway. Biochem. Soc. Trans. 35 Pt 5 (2007) 1088-1091
25. Sudhof T.C. The synaptic vesicle cycle. Annu. Rev. Neurosci. 27 (2004) 509-547
26. i in fibroblasts. J. Cell Sci. 110 Pt 18 (1997) 2227-2238
27. Lloyd-Evans E., et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 14 11 (2008) 1247-1255
28. Miedel M.T., et al. Membrane traffic and turnover in TRP-ML1-deficient cells: a revised model for mucolipidosis type IV pathogenesis. J. Exp. Med. 205 6 (2008) 1477-1490
29. 2+-dependent membrane trafficking in mucolipidosis IV. Biochem. Biophys. Res. Commun. 322 4 (2004) 1384-1391
30. LaPlante J.M., et al. Identification and characterization of the single channel function of human mucolipin-1 implicated in mucolipidosis type IV, a disorder affecting the lysosomal pathway. FEBS Lett. 532 1-2 (2002) 183-187
31. Treusch S., et al. Caenorhabditis elegans functional orthologue of human protein h-mucolipin-1 is required for lysosome biogenesis. Proc. Natl. Acad. Sci. U.S.A. 101 13 (2004) 4483-4488
32. Kiselyov K., Soyombo A., and Muallem S. TRPpathies. J. Physiol. 578 Pt 3 (2007) 641-653
33. Xu H., et al. Activating mutation in a mucolipin transient receptor potential channel leads to melanocyte loss in varitint-waddler mice. Proc. Natl. Acad. Sci. U.S.A. 104 46 (2007) 18321-18326
34. Grimm C., et al. A helix-breaking mutation in TRPML3 leads to constitutive activity underlying deafness in the varitint-waddler mouse. Proc. Natl. Acad. Sci. U.S.A. (2007)
35. Nagata K., et al. The varitint-waddler (Va) deafness mutation in TRPML3 generates constitutive, inward rectifying currents and causes cell degeneration. Proc. Natl. Acad. Sci. U.S.A. 105 1 (2008) 353-358
36. Kim H.J., et al. Gain-of-function mutation in TRPML3 causes the mouse varitint-waddler phenotype. J. Biol. Chem. (2007)
37. Brailoiu E., et al. Essential requirement for two-pore channel 1 in NAADP-mediated calcium signaling. J. Cell Biol. 186 2 (2009) 201-209
38. Calcraft P.J., et al. NAADP mobilizes calcium from acidic organelles through two-pore channels. Nature 459 7246 (2009) 596-600
39. Churchill G.C., et al. NAADP mobilizes Ca (2+) from reserve granules, lysosome-related organelles, in sea urchin eggs. Cell 111 5 (2002) 703-708
40. Furuichi T., Cunningham K.W., and Muto S. A putative two pore channel AtTPC1 mediates Ca (2+) flux in Arabidopsis leaf cells. Plant Cell Physiol. 42 9 (2001) 900-905
41. Pottosin I.I., and Schonknecht G. Vacuolar calcium channels. J. Exp. Bot. 58 7 (2007) 1559-1569
42. + ATPase: molecular structure and function, physiological roles and regulation. J. Exp. Biol. 209 Pt 4 (2006) 577-589
43. Jentsch T.J. CLC chloride channels and transporters: from genes to protein structure, pathology and physiology. Crit. Rev. Biochem. Mol. Biol. 43 1 (2008) 3-36
44. Jentsch T.J. Chloride and the endosomal-lysosomal pathway: emerging roles of CLC chloride transporters. J. Physiol. 578 Pt 3 (2007) 633-640
45. Kasper D., et al. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. Embo J. 24 5 (2005) 1079-1091
46. Paroutis P., Touret N., and Grinstein S. The pH of the secretory pathway: measurement, determinants, and regulation. Physiology (Bethesda) 19 (2004) 207-215
47. Steinberg B.E., et al. In situ measurement of the electrical potential across the phagosomal membrane using FRET and its contribution to the proton-motive force. Proc. Natl. Acad. Sci. U.S.A. 104 22 (2007) 9523-9528
48. Thompson E.G., et al. Lysosomal trafficking functions of mucolipin-1 in murine macrophages. BMC Cell Biol. 8 (2007) 54
49. Soyombo A.A., et al. TRP-ML1 regulates lysosomal pH and acidic lysosomal lipid hydrolytic activity. J. Biol. Chem. 281 11 (2006) 7294-7301
50. Tang Y., Li H., and Liu J.P. Niemann-Pick Disease Type C: From Molecule To Clinic. Clin. Exp. Pharmacol. Physiol. (2009)
51. Pelled D., et al. Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol. Dis. 18 1 (2005) 83-88
52. Wong K., et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. Genet. Metab. 82 3 (2004) 192-207
53. 2+ from the endoplasmic reticulum and an acidic store in the secretory granule area. J. Cell Sci. 119 Pt 2 (2006) 226-238
54. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol. Med. 15 3 (2009) 89-100
55. Duchen M.R., Verkhratsky A., and Muallem S. Mitochondria and calcium in health and disease. Cell Calcium 44 1 (2008) 1-5
56. Korkotian E., et al. Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J. Biol. Chem. 274 31 (1999) 21673-21678
57. Mu T.W., Fowler D.M., and Kelly J.W. Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol. 6 2 (2008) pe26
58. Rigat B., and Mahuran D. Diltiazem, a L-type Ca (2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells. Mol. Genet. Metab. 96 4 (2009) 225-232
59. Reddy J.V., Ganley I.G., and Pfeffer S.R. Clues to neuro-degeneration in Niemann-Pick Type C disease from global gene expression profiling. PLoS One 1 (2006) pe19
60. Sun Y., et al. In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models. PLoS One 4 10 (2009) e7320
61. 2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin. J. Biol. Chem. 278 32 (2003) 29496-29501
62. Deisz R.A., et al. Pathological cholesterol metabolism fails to modify electrophysiological properties of afflicted neurones in Niemann-Pick disease type C. Neuroscience 130 4 (2005) 867-873
63. Tanaka J., et al. Immunohistochemical expression of P400 protein in Purkinje cells of sphingomyelinosis mouse. Brain Dev. 13 2 (1991) 110-114
64. Ginzburg L., and Futerman A.H. Defective calcium homeostasis in the cerebellum in a mouse model of Niemann-Pick A disease. J. Neurochem. 95 6 (2005) 1619-1628
65. 2+ pumps by curcumin. Curcumin putatively stabilizes the interaction between the nucleotide-binding and phosphorylation domains in the absence of ATP. Eur. J. Biochem. 268 23 (2001) 6318-6327
66. Egan M.E., et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304 5670 (2004) 600-602
67. Yuan J.P., et al. TRPC channels as STIM1-regulated SOCs. Channels (Austin) 3 4 (2009) 221-225
68. 2+ channel function. J. Cell Biol. 169 3 (2005) 435-445
69. 2+ store to the plasma membrane. Nature 437 7060 (2005) 902-905
70. Parekh A.B., and Putney Jr. J.W. Store-operated calcium channels. Physiol. Rev. 85 2 (2005) 757-810
71. Kiselyov K., and Muallem S. Mitochondrial Ca (2+) homeostasis in lysosomal storage diseases. Cell Calcium 44 1 (2008) 103-111
72. Di Palma F., et al. Mutations in Mcoln3 associated with deafness and pigmentation defects in varitint-waddler (Va) mice. Proc. Natl. Acad. Sci. U.S.A. 99 23 (2002) 14994-14999
73. Cuajungco M.P., and Samie M.A. The varitint-waddler mouse phenotypes and the TRPML3 ion channel mutation: cause and consequence. Pflugers Arch. (2008)
74. Kim H.J., et al. A novel mode of TRPML3 regulation by extracytosolic pH absent in the varitint-waddler phenotype. Embo J. 27 8 (2008) 1197-1205
75. Venkatachalam K., et al. Motor deficit in a Drosophila model of mucolipidosis type IV due to defective clearance of apoptotic cells. Cell 135 5 (2008) 838-851
76. Kogot-Levin A., et al. Mucolipidosis type IV: the effect of increased lysosomal pH on the abnormal lysosomal storage. Pediatr. Res. 65 6 (2009) 686-690
77. 2+: molecular determinants and functional consequences. Physiol. Rev. 86 1 (2006) 369-408
78. Jolly R.D., et al. Mitochondrial dysfunction in the neuronal ceroid-lipofuscinoses (Batten disease). Neurochem. Int. 40 6 (2002) 565-571
79. 2+ transfer in the control of apoptosis. Oncogene 27 50 (2008) 6407-6418
80. Kiselyov K., et al. Autophagy, mitochondria and cell death in lysosomal storage diseases. Autophagy 3 3 (2007) 259-262
81. Jennings Jr. J.J., et al. Mitochondrial aberrations in mucolipidosis Type IV. J. Biol. Chem. 281 51 (2006) 39041-39050
82. Tessitore A., Pirozzi M., and Auricchio A. Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI. Pathogenetics 2 1 (2009) 4
83. Takamura A., et al. Enhanced autophagy and mitochondrial aberrations in murine G (M1)-gangliosidosis. Biochem. Biophys. Res. Commun. 367 3 (2008) 616-622